Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Oct 19;10(10):CD003426.
doi: 10.1002/14651858.CD003426.pub6.

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Srikanth Nagalla  1 , Samir K Ballas
Affiliations
Meta-Analysis

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Srikanth Nagalla et al. Cochrane Database Syst Rev. .

Abstract

Background: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs. This is an updated version of a previously published review.

Objectives: To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. We also searched online trials registries for any ongoing trials (01 July 2018).Last search of the Group's Haemoglobinopathies Trials Register: 08 October 2018.

Selection criteria: Randomized or quasi-randomized controlled trials of drugs to rehydrate sickled red blood cells compared to placebo or an alternative treatment.

Data collection and analysis: Both authors independently selected studies for inclusion, assessed study quality and extracted data.

Main results: Of the 51 studies identified, three met the inclusion criteria, including 524 people with sickle cell disease aged between 12 and 65 years of age. One study tested the effectiveness of zinc sulphate as compared to placebo and the remaining two assessed senicapoc versus placebo. No deaths were seen in any of the studies (low-quality evidence). The zinc sulphate study showed a significant reduction in painful crises (in a total of 145 participants) over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15) (moderate-quality evidence). However, analysis was restricted due to limited statistical data. Changes to red blood cell parameters and blood counts were inconsistent (very low-quality evidence). No serious adverse events were noted in the study. The Phase II dose-finding study of senicapoc (a Gardos channel blocker) compared to placebo showed that the high dose senicapoc showed significant improvement in change in hemoglobin level, the number and proportion of dense red blood cells, red blood cell count and indices and hematocrit value (very low-quality evidence). The results with low-dose senicapoc were similar to the high-dose senicapoc group but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups (low-quality evidence). A subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control groups in the primary end point of painful crises.

Authors' conclusions: While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to evaluate the effectiveness of this therapy for people with sickle cell disease.While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red blood cell survival (depending on dose), this did not lead to fewer painful crises.Given this is no longer an active area of research, this review will no longer be regularly updated.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Figures

1.1
1.1. Analysis
Comparison 1: Anti‐sickling drug versus placebo, Outcome 1: Mortality
1.2
1.2. Analysis
Comparison 1: Anti‐sickling drug versus placebo, Outcome 2: Number of other serious sickle‐related complications
1.3
1.3. Analysis
Comparison 1: Anti‐sickling drug versus placebo, Outcome 3: Quality of life measures
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ataga 2008 {published data only}
    1. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111(8):3991-7. - PubMed
Ataga 2011 {published data only}
    1. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). British Journal of Haematology 2011;153(1):92-104. - PubMed
Gupta 1995 {published data only}
    1. Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. Journal of the Association of Physicians of India 1995;43(7):467-9. - PubMed

References to studies excluded from this review

Adadevoh 1973 {published data only}
    1. Adadevoh BK, Isaacs WA. The effect of megestrol acetate on sickling. American Journal of the Medical Sciences 1973;265(5):367-70. - PubMed
Adams‐Graves 1997 {published and unpublished data}
    1. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, et al. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997;90(5):2041-6. - PubMed
    1. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D. Rheothrx (Poloxamer 188) injection for the acute painful episode of sickle cell disease (SCD): a pilot study. In: Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program; March 1995. 1995:118.
    1. Adams-Graves P, Mauer A. RheothRx® (poloxamer 188) injection for the acute painful episode of sickle cell disease. Blood 1994;84(Suppl):410a. - PubMed
    1. Emanuele M, Adams-Graves P, Kedar A, Koshy M, Steinberg R, Veith R, et al. RheothRx (Poloxamer 188) lowers serum LDH during an acute painful episode of sickle cell disease. Blood 1996;88(10 (Suppl 1)):13a. - PubMed
Akinsulie 2005 {published data only}
    1. Akinsulie AO, Temiye EO, Akanmu AS, Lesi FE, Whyte CO. Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia. Journal of Tropical Pediatrics 2005;51(4):200-5. - PubMed
Al‐Jam'a 1999 {published data only}
    1. Al-Jam'a AH, Al-Dabbous IA, Rafiq MS, Al-Khatti A, Al-Salem AH, Al-Baharna A, et al. Isoxsuprine in the treatment of sickle cell painful crises: a double-blind comparative study with narcotic analgesia. Annals of Saudi Medicine 1999;19(2):97-100. - PubMed
Alvim 2005 {published data only}
    1. Alvim RC, Viana MB, Pires MA, Franklin HM, Paula MJ, Brito AC, et al. Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. Acta Haematologica 2005;113(4):228-33. - PubMed
Ataga 2002 {published data only}
    1. Ataga KI, Orringer EP, Styles L, Vichinsky E, Swerdlow P, Davis GA, et al. A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of IC 17043 in patients with sickle cell disease (SCD). In: Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program. 2002:41a.
    1. Ataga KI, Orringer EP, Styles L, Vichinsky E, Swerdlow P, Davis GA, et al. A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of ICA-17043 in patients with sickle cell disease (SCD). Blood 2002;100(11 (Part 1 of 2)):454a. - PubMed
Ayra 1996 {published data only}
    1. Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. British Journal of Haematology 1996;93(4):817-21. - PubMed
Bartolucci 2009 {published data only}
    1. Bartolucci P, El Murr T, Roudot-Thoraval F, Habibi A, Santin A, Renaud B, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood 2009;114(18):3742-7. [MEDLINE: ] - PubMed
Beatty 2007 {published data only}
    1. Beatty JR, Calamaras DM, Gamerman SE, Nuuhiwa JKB, Schmidt NA. The effect of guided imagery on pain in children. In: Proceedings of the 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:346.
Benjamin 1986 {published data only}
    1. Benjamin LJ, Berkowitz LR, Orringer E, Mankad VN, Prasad AS, Lewkow LM, et al. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood 1986;67(5):1442-7. - PubMed
Billet 1989 {published data only}
    1. Billett HH, Kaul DK, Connel MM, Fabry ME, Nagel RL. Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease. Nouvelle Revue Francaise d'Hematologie 1989;31(6):403-7. - PubMed
Cabannes 1983 {published data only}
    1. Cabannes R, Sangare A, Cho YW. Acute painful sickle-cell crises in children: a double-blind, placebo-controlled evaluation of efficacy and safety of cetiedil. Clinical Trials Journal 1983;20(4):207-18.
Cabannes 1984 {published data only}
    1. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of Ticlopidine in preventive treatment of sickle cell disease crises. Agents and Actions Supplements 1984;15:199-212. - PubMed
De Abood 1997 {published data only}
    1. De Abood M, Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera® or Microgynon® on the painful crises of sickle cell anemia patients. Contraception 1997;56(5):313-6. - PubMed
De Ceulaer 1982 {published data only}
    1. De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle cell disease. Lancet 1982;2(8292):229-31. - PubMed
    1. De Ceulaer K, Gruber C, Serjeant G. Effect of depo-provera on the haematological and clinical features of homozygous sickle cell disease. In: Proceedings of the Commonwealth Caribbean Medical Research Council, 27th Scientific Meeting; 1982 April 14-17; Trinidad and Tobago. 1982:47.
De Ceulaer 1990 {published data only}
    1. De Ceulaer K, Serjeant GR, Nagel RL, Billett HH, Christakis J, Loukopoulos D, et al. Intravenous oxypentifylline and the painful crisis of sickle cell disease. Clinical Hemorheology 1990;10(1):35-42.
Gail 1982 {published data only}
    1. Gail M, Beach J, Dark A, Lewis R, Morrow H. A double-blind randomized trial of low-dose urea to prevent sickle cell crises. Journal of Chronic Diseases 1982;35(2):151-61. - PubMed
Gladwin 2011 {published data only}
    1. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011;305(9):893-902. [MEDLINE: ] - PMC - PubMed
Godeau 2003 {published data only}
    1. Godeau B, Roudet-Thoraval F, Havivi A, Elmur T, Bachir D, Paul M, et al. Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease. A randomized double blind monocentric study. Blood 2003;102(11):2824a.
Isaacs 1971 {published data only}
    1. Isaacs WA, Effiong CE, Ayeni O. Steroid treatment in the prevention of painful episodes in sickle-cell disease. Lancet 1972;1(7750):570-1. - PubMed
    1. Isaacs WA. The effect of certain lipid substances on sickling. Acta Haematologica 1971;45(4):259-65. - PubMed
Jacobson 1997 {published and unpublished data}
    1. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet 1997;350(9088):1358-61. - PubMed
    1. Kopesky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clinical Pharmacology and Therapeutics 2004;75(3):140-6. - PubMed
Lonsdorfer 1984 {published data only}
    1. Lonsdorfer J, Castaigne JP, Lenormand E, Otayeck A, Bogui P, Dosso Y, et al. Beneficial effects of Ticlopidine on cardiopulmonary function of sickle cell patients not in crisis. Agents and Actions Supplements 1984;15:213-8. - PubMed
Mahmood 1969 {published data only}
    1. Mahmood A. A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia. British Journal of Haematology 1969;16(1):181-4. - PubMed
Manion 2001 {published data only}
    1. Manion C, Parkhurst JB, Ogle B, Johnson A, Edmundson A. Aspartame inhibits hypoxia-induced sickling of erythrocytes in patients with sickle cell disease. In: Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program. 2000:172a.
    1. Manion CV, Howard J, Ogle B, Parkhurst J, Edmundson A. Aspartame effect in sickle cell anemia. Clinical Pharmacology and Therapeutics 2001;69(5):346-55. - PubMed
Manrique 1987 {published data only}
    1. Manrique RV. Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. Journal of Medicine 1987;18(5&6):277-91. - PubMed
Orringer 1991 {published data only}
    1. Orringer E, Huffman J, Johnson A, Jones S, Whitney J, Brockenbrough S, et al. A clinical study of the safety, pharmacokinetics and pharmacodynamics of intravenous infusions of 12C79 in sickle cell disease patients not in crisis. In: Proceedings of the 16th Annual Meeting of the National Sickle Cell Disease Program; March 1991. 1991:112.
    1. Orringer EP, Binder EA, Thomas RP, Blythe DS, Bustrack JA, Schroeder DH, et al. Phase 1 study of BW 12C in sickle cell disease (SCD) patients not in crisis. Blood 1988;5(Suppl 1):69a.
    1. Orringer EP, Binder EA, Thomas RP, Blythe DS, Bustrack JA, Schroeder DH, et al. Phase I study of 12C79 in sickle cell disease (SCD) patients not in crisis. In: Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program. 1989:57.
Osamo 1981 {published data only}
    1. Osamo NO, Photiades DP, Famodu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematologica 1981;66(2):102-7. - PubMed
Oski 1968 {published data only}
    1. Oski F, Call FL, Lessen L. Failure of promazine HCl to prevent the painful episodes in sickle cell anemia. Journal of Pediatrics 1968;73(2):265-6. - PubMed
Oyewo 1987 {published data only}
    1. Oyewo EA. Therapeutic effect of diflusinal as prophylaxis in sickle cell anaemia. Clinical Trials Journal 1987;24(3):249-53.
Pace 2003 {published data only}
    1. Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. American Journal of Hematology 2003;73(1):26-32. - PubMed
Pichard 1987 {published data only}
    1. Pichard E, Duflo B, Coulibaly S, Mariko B, Monsempes JL, Traore HA, et al. Effectiveness of treatment during osteoarticular pain crises in drepanocytosis; based on the example of pentoxifylline [Evaluation de L'efficacite des traitements au cours des crises douloureuses osteo-articulaires de la drepanocytose exemple de la pentoxifylline]. Bulletin de la Societe de Pathologie Exotique et de ses Filiales (Paris) 1987;80(5):834-40. - PubMed
Piracetam Study 1998 {published data only}
    1. El-Hazmi AF, Warsy AS, Al-Fawaz I, Farid M, Refai S, Opawoye AD, et al. Piracetam in the treatment of sickle cell disease. In: Proceedings of the 20th Annual Meeting of the National Sickle Cell Disease Program. 1995:162a.
    1. El-Hazmi MAF, Warsy AS, Al-Fawaz I, Opawoye AD, Abu Taleb H, Howsawi Z, et al. Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematologica 1996;96(4):221-6. - PubMed
    1. The Piracetam Study Group. Piracetam for the treatment of sickle cell disease in children - a double blind test. Saudi Medical Journal 1998;19(1):22-7. - PubMed
Poflee 1991 {published data only}
    1. Poflee VW, Gupta OP, Jain AP, Jajoo UN. Haemorheological treatment of painful sickle cell crises: use of pentoxifylline. Journal of the Association of Physicians India 1991;39(8):608-9. - PubMed
Qari 2007 {published data only}
    1. Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis 2007;98(2):392-6. - PubMed
Rubio 1992 {published data only}
    1. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clinical Pharmacokinetics 1992;22(3):238-46. - PubMed
    1. Rubio A, Weintraub M. Scoring system in a pilot effectiveness study of patients with sickle cell anemia. Journal of Clinical Research and Pharmacoepidemiology 1992;6:47-54.
Semple 1984 {published data only}
    1. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of Ticlopidine in sickle cell disease. Thrombosis and Haemostasis 1984;51(3):303-6. - PubMed
Silva‐Pinto 2007 {published data only}
    1. Silva-Pinto AC, Carrara RC, Oliveira VC, Palma PV, Campos AD, Zago MA, Covas DT. Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume. Haematologica 2007;92(Suppl 1):298.
Teuscher 1988 {published data only}
    1. Teuscher T, Weil Von Der Ahe C, Baillod P, Holzer B. Double blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis. Tropical and Geographical Medicine 1989;41(4):320-5. - PubMed
Toppet 2000 {published data only}
    1. Toppet M, Fall ABK, Ferster A, Fondu P, Melot C, Vanhaelen-Fastre R, et al. Antisickling activity of sodium cromoglicate in sickle-cell disease [letter]. Lancet 2000;356(9226):309. - PubMed
Urea Trial 1974 {published data only}
    1. Cooperative Urea Trials Group. Clinical trials of therapy for sickle cell vaso-occlusive crises. Journal of the American Medical Association 1974;228(9):1120-4. - PubMed
Urea Trial 2 1974 {published data only}
    1. Cooperative Urea Trials Group. Treatment of sickle cell crisis with urea in invert sugar. A controlled trial. JAMA 1974;228(9):1125-8. - PubMed
Urea Trial 3 1974 {published data only}
    1. Cooperative Urea Trials Group. Controlled clinical trials and cooperative study of intravenously administered alkali. JAMA 1974;228(9):1129-31. - PubMed
Uzun 2010 {published data only}
    1. Uzun B, Kekec Z, Gurkan E. Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis. American Journal of Emergency Medicine 2010;28(4):445-9. [MEDLINE: ] - PubMed
Wallen 2007 {published data only}
    1. Wallen GR, Handel D, Mendoza J, Chestnut W, Nichols J, Yates J, et al. A randomized pilot study exploring hypnosis as a pain and symptom management strategy in patients with sickle cell disease. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA.. 2007:261.
Wambebe 2001 {published data only}
    1. Fonnebo V. Indigenous Nigerian medicinal plants may be useful in the management of sickle-cell disorder. Focus on Alternative and Complementary Therapies 2002;7(2):146.
    1. Wambebe C, Khamofu H, Momoh JAF, Ekpeyong M, Audu BS, Njoku OS, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder. Phytomedicine 2001;8(4):252-61. - PubMed
    1. Wambebe C. Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia. In: Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program. 2002:46a.
    1. Wambebe CO, Bamgboye EA, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, et al. Efficacy of niprisan in the prophylactic management of patients with sickle cell disease. Current Therapeutic Research, Clinical and Experimental 2001;62(1):26-34.
Weiner 2002 {published data only}
    1. Weiner DL, Hibberd PL, Betit P, Botelho CA, Cooper AB, Brugnara C. Inhaled nitric oxide for treatment of acute vaso-occlusive crisis in sickle cell disease. Blood 2002;100(11 Pt 1):11a. - PubMed
    1. Weiner DL, Hibberd PL, Betit P, Brugnara C. Effectiveness and safety of inhaled nitric oxide for the treatment of vaso-occlusive crisis in pediatric sickle cell disease. Pediatric Research 2002;51(4 Suppl):86A.
    1. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003;289(9):1136-42. - PubMed
Wynn 2007 {published data only}
    1. Wynn L, Debenham E, Faughnan L, Martin B, Kelly T, Reed C, et al. Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245.
Zago 1984 {published data only}
    1. Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematologica 1984;72(1):61-4. - PubMed

Additional references

Adrie 2000
    1. Adrie C, Kister J, De Franceschi L, Rouyer-Fessard P, Kieger L, Marden M, et al. Nitric oxide restores the erythrocyte density of the SAD mouse model of sickle cell disease. Blood 2000;96(11):Parts 1 and 2.
Al Hajeri 2007
    1. Al Hajeri AA, Fedorowicz Z, Omran A, Tadmouri GO. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No: CD006111. [DOI: 10.1002/14651858.CD006111.pub2] - DOI - PubMed
Ballas 1989
    1. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. American Journal of Hematology 1989;32(2):104-11. - PubMed
Ballas 2000
    1. Ballas SK. Hydration of sickle erythrocytes using a naturally occurring sodium ionophore. Blood 2000;96(11):Parts 1 and 2.
Bennekou 2000
    1. Bennekou P, Pederson O, Moller A, Christopherses P. Volume control in sickle cells is facilitated by novel anion conductance inhibitor NS1652. Blood 2000;95(5):1842-8. - PubMed
Bennekou 2001
    1. Bennekou P, Franceschi L, Pedersen O, Lian L, Asakura T, Evans G, et al. Treatment with NS3623, a novel Cl-conductance blocker, amiliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood 2001;97(5):1451-7. - PubMed
Brugnara 1987
    1. Brugnara C, Tosteson DC. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood 1987;70(6):1810-5. - PubMed
Brugnara 1993
    1. Brugnara C, De Franceschi L, Alper SL. Inhibition of Ca2+activated K + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. Journal of Clinical Investigation 1993;92(1):520-6. - PMC - PubMed
Brugnara 1995
    1. Brugnara C. Red cell dehydration in pathophysiology and treatment of sickle cell disease. Current Opinion in Hematology 1995;2(2):132-8. - PubMed
Brugnara 1996
    1. Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation 1996;97(5):1227-34. - PMC - PubMed
Charache 1995
    1. Charache S, Terrin M, Moore R, Dover G, Barton F, Eckert S, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995;332(20):1317-22. - PubMed
Davies 1997
    1. Davies SC, Oni L. Management of patients with sickle cell disease. BMJ 1997;315(7109):656-60. - PMC - PubMed
de Franceschi 1994
    1. Franceschi L, Saadane N, Trudel M, Alper S L, Brugnara C, Beuzard Y. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.. Journal of Clinical Investigation 1994;93(4):1670-6. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Gibson 1998
    1. Gibson X A, Shartava A, McIntyre J, Monteiro C A, Zhang Y, Shah A, et al. The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro. Blood 1998;91(11):4373-8. - PubMed
Gibson 2000
    1. Gibson JS, Stewart GW, Ellory JC. Effect of dimethyl adipimidate on K+ transport and shape change in red blood cells from sickle cell patients. FEBS Letters 2000;480(2-3):179-83. - PubMed
Gini 1987
    1. Gini EK, Sonnet J. Use of piracetam improves sickle cell deformability in vitro and in vivo. Journal of Clinical Pathology 1987;40(1):99-102. - PMC - PubMed
Gupta 1987
    1. Gupta VL, Chaubey BS. Red blood cell survival, zinc deficiency and efficacy of zinc therapy in sickle cell disease. In: Fucharoen S, Rowley PT, Paul NW, editors(s). Thalassemia: pathophysiology and management, part A. Vol. 23. New York: Alan R Liss Inc, 1987:477-83. - PubMed
Hankins 2008
    1. Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology 2008;140(1):80-5. - PubMed
Hickman 1999
    1. Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al. Mapping the prevalence of sickle cell disease and beta thalassaemia in England: estimating and validating ethnic-specific rates. British Journal of Haematology 1999;104(4):860-7. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-600. - PMC - PubMed
Jones 2001
    1. Jones AP, Davies SC, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No: CD002202. [DOI: 10.1002/14651858.CD002202] - DOI - PubMed
Karayalcin 1974
    1. Karayalcin G, Rosner F, Kim KY, Chandra P. Plasma-zinc in sickle cell-anaemia [letter]. Lancet 1974;1(7850):217. - PubMed
Leikin 1989
    1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989;84(3):500-8. - PubMed
Prasad 1981
    1. Prasad AS, Abbasi AA, Rabbani P, DuMouchelle E. Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects. American Journal of Hematology 1981;10(2):119-27. - PubMed
Prasad 1999
    1. Prasad AS, Beck FWJ, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). American Journal of Hematology 1999;61(3):194-202. - PubMed
Qureshi 2000
    1. Qureshi MA, Gugnani MK, Swerdlow PS, Girgis RE. Decreased exhaled nitric oxide (NO) in patients with sickle cell disease. Blood 2000;96(11 (Pt 1 and 2)).
Rivera 2000
    1. Rivera A, Brugnara C. Vaso-active molecules modulate Gardos channel activity and hydration state of normal and sickle erythrocytes. In: Blood. Vol. 96. 2000.
Romero 2000
    1. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice: effects on red cell density and potassium transport. Blood 2000;96(11 (Pt 1 and 2)). - PubMed
Romero 2002
    1. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002;99(4):1103-8. - PubMed
Serjeant 1970
    1. Serjeant GR, Galloway RE, Gueri MC. Oral zinc sulphate in sickle-cell ulcers. Lancet 1970;2(7679):891-2. - PubMed
Serjeant 1992
    1. Serjeant GR. Sickle cell disease. 2nd edition. New York: Oxford Medical Publications, 1992.
Stocker 2000
    1. Stocker J, De Franceschi L, McNaughton-Smith G, Brugnara C. A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease. Blood 2000;96(11 (Pt 1 and 2)). - PubMed
Stocker 2003
    1. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003;101(6):2412-8. - PubMed
Stone 1988
    1. Stone PCW, Chalder SM, Stuart J. Action of piracetam on cation flux and deformability of sickle cells. Clinical Hemorheology 1988;8(5):779-90.
Stuart 1990
    1. Stuart J, Stone PCW, Nash GB, Ellory JC. Effect of Piracetam on Ca2+-induced K+ efflux from sickle cells. Clinical Hemorheology 1990;10(5):535-40.
Stuart 1992
    1. Stuart J. Rheological consequences of sickle-cell dehydration. Clinical Hemorheology 1992;12(2):203-16.
Zemel 2001
    1. Zemel B, Kawchak D, Fung E, Ohene-Frempong K, Stallings V. Zinc supplementation and linear growth in children with sickle cell disease: a pilot study. In: Proceedings of the 25th Annual Meting of the National Sickle Cell Disease Program; April 2001; New York. 2001:Abst #232.

References to other published versions of this review

Nagalla 2010
    1. Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003426. [DOI: 10.1002/14651858.CD003426.pub3] - DOI - PubMed
Nagalla 2012
    1. Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No: CD003426. [DOI: 10.1002/14651858.CD003426.pub4] - DOI - PubMed
Riddington 2002
    1. Riddington C, De Franceschi L. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No: CD003426. [DOI: 10.1002/14651858.CD003426.pub2] - DOI - PubMed
Singh 2007
    1. Singh PC, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No: CD003426. [DOI: 10.1002/14651858.CD003426.pub2] - DOI - PubMed

Publication types

MeSH terms